CL2017000360A1 - Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon - Google Patents

Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon

Info

Publication number
CL2017000360A1
CL2017000360A1 CL2017000360A CL2017000360A CL2017000360A1 CL 2017000360 A1 CL2017000360 A1 CL 2017000360A1 CL 2017000360 A CL2017000360 A CL 2017000360A CL 2017000360 A CL2017000360 A CL 2017000360A CL 2017000360 A1 CL2017000360 A1 CL 2017000360A1
Authority
CL
Chile
Prior art keywords
receptor
fib
antibodies directed
new antibodies
epsilon
Prior art date
Application number
CL2017000360A
Other languages
English (en)
Inventor
Carle Anna
Sondermann Peter
Mueller Martina
Rieth Nicole
Pohl Thomas
Direnberger Carolin
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of CL2017000360A1 publication Critical patent/CL2017000360A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>SE DIVULGAN EN LA PRESENTE MOLÉCULAS DE RECONOCIMIENTO QUE SE UNEN CON UN PRIMER DOMINIO DE UNIÓN AL RECEPTOR DE Fc ÉPSILON (Fc?R) Y CON UN SEGUNDO DOMINIO DE UNIÓN AL RECEPTOR IIB DE Fc GAMMA (Fc· RIIB), ASÍ COMO TAMBIÉN USOS PARA DICHAS MOLÉCULAS DE RECONOCIMIENTO.</p>
CL2017000360A 2014-08-13 2017-02-10 Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon CL2017000360A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14002825 2014-08-13

Publications (1)

Publication Number Publication Date
CL2017000360A1 true CL2017000360A1 (es) 2017-07-14

Family

ID=51355407

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000360A CL2017000360A1 (es) 2014-08-13 2017-02-10 Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon

Country Status (19)

Country Link
US (1) US10730946B2 (es)
EP (1) EP3180358B1 (es)
JP (1) JP6808611B2 (es)
KR (1) KR102424169B1 (es)
CN (1) CN106795223B (es)
AR (1) AR101555A1 (es)
AU (1) AU2015303142B2 (es)
BR (1) BR112017002755B1 (es)
CA (1) CA2957850A1 (es)
CL (1) CL2017000360A1 (es)
CO (1) CO2017001384A2 (es)
EA (1) EA035269B1 (es)
ES (1) ES2802176T3 (es)
IL (1) IL250569B (es)
MX (1) MX382543B (es)
MY (1) MY180940A (es)
SG (1) SG11201701028SA (es)
TW (1) TWI713464B (es)
WO (1) WO2016023985A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CA2957850A1 (en) 2014-08-13 2016-02-18 Suppremol Gmbh Antibodies comprising binding domains to fc.epsilon. receptor (fc.epsilon.r) and fc gamma receptor iib (fc.gamma.riib)
WO2018036947A1 (en) * 2016-08-22 2018-03-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inhibiting biological responses induced by a receptor that uses pi3k to signal in a cell
EP3840841A1 (en) 2018-08-23 2021-06-30 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
KR20220070215A (ko) * 2019-10-01 2022-05-30 엡실로겐 리미티드 하이브리드 항체
JP7627413B2 (ja) * 2020-08-21 2025-02-06 ファチアブジェン インコーポレイテッド ガンマ定常領域（Ｃγ１）とイプシロン定常領域（Ｃε２－４）とが融合された重鎖及び軽鎖の定常領域からなる抗体断片及びその用途
CN113214392B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体ky031、制备方法及用途
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254753C1 (en) * 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
AU2004293184B2 (en) * 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
SG173322A1 (en) * 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CA2957850A1 (en) 2014-08-13 2016-02-18 Suppremol Gmbh Antibodies comprising binding domains to fc.epsilon. receptor (fc.epsilon.r) and fc gamma receptor iib (fc.gamma.riib)

Also Published As

Publication number Publication date
CN106795223B (zh) 2021-05-04
KR102424169B1 (ko) 2022-07-25
AR101555A1 (es) 2016-12-28
SG11201701028SA (en) 2017-03-30
BR112017002755B1 (pt) 2023-12-26
WO2016023985A1 (en) 2016-02-18
EA035269B1 (ru) 2020-05-22
US20170226208A1 (en) 2017-08-10
EP3180358A1 (en) 2017-06-21
MY180940A (en) 2020-12-14
CA2957850A1 (en) 2016-02-18
EA201790314A1 (ru) 2017-06-30
US10730946B2 (en) 2020-08-04
KR20170041250A (ko) 2017-04-14
IL250569B (en) 2021-05-31
JP6808611B2 (ja) 2021-01-06
MX2017001895A (es) 2017-08-28
TW201629099A (zh) 2016-08-16
MX382543B (es) 2025-03-13
BR112017002755A2 (pt) 2017-12-19
CO2017001384A2 (es) 2017-05-10
JP2017529832A (ja) 2017-10-12
CN106795223A (zh) 2017-05-31
EP3180358B1 (en) 2020-04-01
ES2802176T3 (es) 2021-01-15
AU2015303142A1 (en) 2017-03-02
TWI713464B (zh) 2020-12-21
IL250569A0 (en) 2017-03-30
AU2015303142B2 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CL2017000360A1 (es) Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc épsilon
CL2017001314A1 (es) Célula
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CL2017002413A1 (es) Receptor antigénico quimérico
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
MX383829B (es) Anticuerpo que une erbb-2 y erbb-3.
CL2018000270A1 (es) Constructos de anticuerpo para cd70 y cd3.
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
CO2017013331A2 (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
CL2017000438A1 (es) Sistema de señalización
CR20130376A (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX370807B (es) Anticuerpos que se unen a axl.
MX2017001457A (es) Divisores de union dinamicos para ventanas de aplicacion.
MX2016000231A (es) Receptor de celulas t de la alta estabilidad y metodo de preparacion y aplicacion del mismo.
CL2017000110A1 (es) Moléculas con especificidad para dc79 y cd22
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
BR112015018851A2 (pt) anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CL2015001127A1 (es) Nuevas variantes del receptor iib de fc gamma